← IndicationsOpen filtered programs
Landscape
Age-Related Hearing Loss
Age-Related Hearing Loss has 12 tracked records across 9 named organizations, including 3 strong-evidence records and 6 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.
12
Pipeline Records
strong evidence + caveats + candidates
3
Strong Evidence
9 checked records with caveats
6
Active Programs
currently active
0
Marketed / Approved
commercial or approved
9
Organizations
companies, sponsors, and institutions
Competitive Density
27/100
organization breadth + program volume
Pipeline Velocity
38/100
active and late-stage share
Evidence Coverage
25/100
share strong evidence
Completion Signal
8/100
late-stage, approved, or marketed
Attrition Rate
8/100
share discontinued
Concentration
33/100
top-organization share
Programs by Stage
Preclinical2 · 17%
Phase 11 · 8%
Phase 1/22 · 17%
Phase 23 · 25%
Phase 31 · 8%
Interventional/NA2 · 17%
Not applicable1 · 8%
Trial / Program Status
Active6 · 50%
Completed4 · 33%
Discontinued1 · 8%
Paused1 · 8%
Modality Breakdown
Small Molecule9 · 75%
Regenerative Medicine2 · 17%
Cell Therapy1 · 8%
Program Types
Therapeutic12 · 100%
Top Organizations
Institution-led study4 · 33%
Acousia Therapeutics GmbH1 · 8%
Autifony Therapeutics Limited1 · 8%
Biogen1 · 8%
Boehringer Ingelheim1 · 8%
Hangzhou PhecdaMed Co., Ltd.1 · 8%
Otonomy1 · 8%
Phafag AG1 · 8%
Population Tags
age-related11 · 92%
adult10 · 83%
older-adult7 · 58%
tinnitus4 · 33%
noise-induced2 · 17%
sensorineural2 · 17%
auditory-neuropathy1 · 8%
central-auditory-processing-disorder1 · 8%
cisplatin-ototoxicity1 · 8%
cochlear-implant1 · 8%
Strong-Evidence Programs
3 recordsRincell-1 by Rinri TherapeuticsStrong evidence
Company: Rinri Therapeutics · Phase 1/2 · Active
Cell TherapyPhase 1/2Active92% confidence
ACOU085 by Acousia TherapeuticsStrong evidence
Company: Acousia Therapeutics GmbH · Phase 2 · Active
Small MoleculePhase 2Active93% confidence
AOK-1Strong evidence
Company: Boehringer Ingelheim · Preclinical · Active
Regenerative MedicinePreclinicalActive82% confidence
Checked Records With Caveats
9 recordsOTO-6XX by Otonomy
Company: Otonomy · Preclinical · Discontinued
Regenerative MedicinePreclinicalDiscontinued84% confidence
PF-04958242 by Biogen/Pfizer for age-related hearing lossStatus caveat
Company: Biogen · Phase 1 · Completed
Small MoleculePhase 1Completed88% confidence
AUT00063 by Autifony TherapeuticsStatus caveat
Company: Autifony Therapeutics Limited · Phase 2 · Completed
Small MoleculePhase 2Completed86% confidence
Hormone replacement therapy auditory-aging exposure studyStatus caveat
Sponsor / Institution: Institution-led study · Not applicable · Completed
Small MoleculeNot applicableCompleted84% confidence
Fudan huperzine A presbycusis/tinnitus studyStatus caveat
Sponsor / Institution: Institution-led study · Interventional/NA · Active
Small MoleculeInterventional/NAActive82% confidence
Colorado LOOT clemastine plus engineered sound CAPD studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 1/2 · Active
Small MoleculePhase 1/2Active82% confidence
Shanghai Liuwei Dihuang Pill presbycusis studyStatus caveat
Sponsor / Institution: Institution-led study · Phase 2 · Completed
Small MoleculePhase 2Completed82% confidence
Transtympanic caroverine by PhafagStatus caveat
Company: Phafag AG · Phase 3 · Paused
Small MoleculePhase 3Paused80% confidence
TJ0113 Capsules by Hangzhou PhecdaMedStatus caveat
Company: Hangzhou PhecdaMed Co., Ltd. · Interventional/NA · Active
Small MoleculeInterventional/NAActive78% confidence